China Resources Double-Crane Pharmaceutical (SHA:600062) unit CR Saike obtained drug registration from China's drug regulator for ezetimibe tablets.
The drug is used to treat primary hypercholesterolemia, homozygous familial hypercholesterolaemia, and sitosterolemia, according to a Tuesday filing with the Shanghai bourse.
Shares of the pharmaceutical company were down 1% in recent trade.